Your first 90 days
Your first 90 days on Uplizna for generalized myasthenia gravis
What happens before the first fill, the days that matter, the label's rules and who to call, from the label, the drugmaker's own program and one insurer's written rules.
Uplizna is given twice a year after its 2 starting infusions, and the start takes some planning. Three screening tests, any needed vaccines and an insurance approval come before the first infusion. Then 2 infusions arrive 2 weeks apart, and the next one is about 6 months away. This page lays out that stretch from the FDA label, Amgen's support program and one insurer's written rules.
What has to happen before the first bottle ships
Uplizna has no REMS, so the first infusion waits on 3 screening tests, any needed vaccines, an insurance approval and a place to receive it. These are the 8 things in the way, in order.
A positive AChR or MuSK antibody test
The myasthenia gravis approval covers adults who test positive for acetylcholine receptor (AChR) or muscle-specific tyrosine kinase (MuSK) antibodies.
- The trial in the label enrolled only people with one of those 2 antibodies.FDA label
A hepatitis B blood test
The label requires hepatitis B screening before the first dose.
- Uplizna is not given to anyone with active hepatitis B. If a past infection or carrier status shows up, the label asks your neurologist to involve a liver specialist before and during treatment.FDA label
A tuberculosis check
The label asks your neurologist to check for active tuberculosis and test for a hidden (latent) infection.
- Uplizna is not given with active or untreated latent tuberculosis.
- An infectious disease specialist may weigh in on treating it first.FDA label
An antibody level test
The label requires a blood test of your immunoglobulin levels before the first dose.
- If your levels are low, it asks your neurologist to consult an immunology expert before starting.FDA label
Vaccines at least 4 weeks ahead
The label asks for all vaccines to be given by the usual guidelines at least 4 weeks before the first infusion.
- Live vaccines are not recommended during treatment or until your B cells recover after stopping.FDA label
Your other medicines
Tell your neurologist about every medicine that affects your immune system, including steroids and other myasthenia gravis treatments.
- The label says using them with Uplizna may raise the risk of infection.FDA label
Enrollment and the insurance check
You can call Amgen By Your Side, or your doctor's office can enroll you online with your consent.
- After you sign a HIPAA release, the team checks your coverage, your likely costs and whether a prior authorization is needed.Amgen insurance page
Where each infusion will happen
Amgen says a Patient Access Liaison can help you find an infusion center.
- It says home infusion may be an option, and to ask your doctor and insurance provider about it.Starting Uplizna
The days that matter
Counted from the first infusion, with the screening tests and vaccine window before it, the second starting infusion on day 15 and the next dose about 6 months out. Type your first-dose date and the tiles become real dates you can add to your calendar.
The tiles below count days from a first dose. Enter the date of yours, or the date you expect, and each tile becomes a real date on your calendar.
The date stays on your device. It is not sent to Trial Friend or anyone else. The calendar file works with Apple, Google and Outlook calendars.Enrollment and the benefits check
The office or you enroll in Amgen By Your Side, and a Patient Access Liaison reviews your coverage.
- No source sets how long this takes, because each insurer works on its own timeline.
Hepatitis B, tuberculosis and antibody tests
All 3 are required before the first dose.
- Results that need a liver, infectious disease or immune specialist can add time before the first infusion.
Last day for vaccines
The label asks for any needed vaccines, live or not, at least 4 weeks before the first infusion.
- The Medication Guide says to talk to your healthcare provider before any vaccination.
Approval, then booking the infusion
Once the plan approves, the first 2 infusions can be booked 2 weeks apart.
- Amgen says your liaison can help find an infusion center and coordinate appointments.
First infusion, 300mg
A steroid comes about 30 minutes before, with an antihistamine and a fever reducer 30 to 60 minutes before.
- The drip speeds up in steps over about 90 minutes, and staff watch you for at least 1 hour after.
Infusion reactions are most common with the first infusion
Reactions such as headache, nausea, sleepiness, shortness of breath, fever, muscle aches, rash or palpitations can happen.
- The Medication Guide says to tell your healthcare provider right away.
- The myasthenia gravis trial counted reactions during the infusion and in the 24 hours after it.
Second starting infusion, 300mg
The same premedicines, the same 90 minutes and the same hour of watching.
- Before every infusion, the label asks staff to check for an active infection and to delay the dose until it clears.
B cells are down
In the myasthenia gravis trial, B cell counts fell below normal by week 4 in at least 99% of patients on Uplizna.
- They stayed below normal in at least 96% through the controlled part of the trial.
- The label warns that serious infections, some fatal, have occurred with medicines that lower B cells, including Uplizna.
Antibody levels over time
The label asks your neurologist to keep checking immunoglobulin levels during treatment and after stopping, until B cells recover.
- It sets no fixed schedule, and it stresses checks when infections keep coming back.
Next dose about 6 months from day 1
The FEP policy below approves up to 9 vials in the first 12 months.
- At 3 vials per infusion, that covers both starting doses and the dose at month 6.
The label, revision by revision
The FDA lists which sections changed in each revision of a label. These are the revisions the current Uplizna label records, dated by the FDA, with a plain note on what each one meant for a patient. Older references and handouts can lag these by months.
Current label dated September 21, 2026, read from the FDA's label database today. FDA label
- September 2026
The FDA label added instructions for drawing Uplizna from the vial, using a fine needle and no vial spikes or closed transfer devices. The dose, tests and warnings did not change.FDA label
- December 2025
The FDA added generalized myasthenia gravis for adults with AChR or MuSK antibodies, with the same dose schedule as the earlier uses. The label's warnings on infusion reactions and infections were revised in the same month.FDA letter
- April 2025
The FDA added IgG4-related disease as a second use.FDA letter
- June 2020
The FDA first approved Uplizna, for adults with NMOSD who are AQP4 antibody positive.FDA letter
How the label says to take it
The parts of the prescribing information and the patient leaflet that come up in the first 3 months, in plain words.
- Two starting doses, then every 6 months
The label gives 300mg, then another 300mg 2 weeks later.
- After that, one 300mg infusion comes every 6 months, counted from the first infusion.FDA label
- The same dose for everyone
The dose does not depend on your weight.
- Each carton holds three 100mg vials, and all 3 go into one 250mL bag of salt water for a single infusion.FDA label
- Medicines before every infusion
The label calls for a steroid by IV, such as methylprednisolone, about 30 minutes before.
- It also calls for an antihistamine, such as diphenhydramine, and a fever reducer, such as acetaminophen, by mouth 30 to 60 minutes before.FDA label
- How the infusion is given
Uplizna goes into a vein through a pump and a filter, starting slowly and moving through 3 rising speeds.
- It takes about 90 minutes in total.FDA label
- What to bring
Amgen suggests planning ahead for the visit.
- Its list is a bottle of water, a light snack and something to pass the time, such as a book, podcast or playlist.Starting Uplizna
- Watching after each infusion
Staff watch you closely during the infusion and for at least 1 hour after it ends.
- If a reaction happens, they may slow or stop the infusion and treat your symptoms.
- A life-threatening reaction means Uplizna is stopped for good.FDA label
- Infections delay a dose
Before every infusion, staff check for an active infection.
- The label says to wait until it clears.
- Infections can still happen after your last dose, so the label asks you to keep reporting them.FDA label
- Pregnancy and birth control
Uplizna may harm an unborn baby, based on animal studies.
- The label advises effective birth control during treatment and for 6 months after the last infusion.
- A pregnancy registry takes calls at 1-303-724-4644.FDA label
- If you were on Uplizna while pregnant
The Medication Guide asks you to tell your baby's healthcare provider.
- The label says the baby should not get live vaccines until tests show the baby's B cells have recovered.FDA label
- Breastfeeding
It is not known whether Uplizna passes into breast milk.
- The Medication Guide asks you to talk with your healthcare provider about the best way to feed your baby.FDA label
What the label says to act on
The symptoms the label singles out, and what it tells patients and prescribers to do about each. If any of these happen, the label's instruction is the one to follow, with your care team.
Signs of an infusion reaction
Headache, nausea, sleepiness, shortness of breath, fever, muscle aches, rash or palpitations.
- The Medication Guide says to tell your healthcare provider right away.
- The Medication Guide says reactions can include anaphylaxis, can be serious and may lead to a hospital stay.
- Reactions occurred in 10.1% of myasthenia gravis trial patients on Uplizna, and the label says they are most common with the first infusion.FDA label
Signs of infection
Painful and frequent urination, nasal congestion, runny nose, sore throat, fever, chills, cough or body aches.
- The Medication Guide says to tell your healthcare provider right away.
- In the myasthenia gravis trial, the most common infections were urinary tract infection and nasopharyngitis (a cold), at 7% each.FDA label
Signs of PML, a rare brain infection
Weakness on one side of the body, loss of coordination in your arms and legs, vision changes, changes in thinking or memory, confusion or personality changes.
- The Medication Guide says to call your healthcare provider right away.
- The label says no confirmed case was found in Uplizna trials.FDA label
Hepatitis B coming back
If you have ever had hepatitis B, it may become active again during or after treatment and cause serious liver problems.
- The label reports this in a patient in the myasthenia gravis trial.
- The Medication Guide says your provider will monitor you if you are at risk.FDA label
Antibody levels that fall
The label says immunoglobulin (antibody) levels may keep falling with continued treatment.
- At week 26 of the myasthenia gravis trial, IgG was below normal in 29% on Uplizna against 8% on placebo.
- For IgM, the figures were 16% against 4%.FDA label
Low blood cell counts
The Medication Guide says Uplizna may lower some types of blood cells, and your provider will do blood tests to check.
- In the myasthenia gravis trial, lymphocyte counts were below normal in 35% on Uplizna against 31% on placebo.FDA label
Headache and other common side effects
In the myasthenia gravis trial, headache occurred in 15% on Uplizna against 7% on placebo.
- Infusion-related reactions occurred in 10% against 6%.
- Nasopharyngitis, cough and urinary tract infection each occurred in 7% against 3%.FDA label
Why the pharmacy or the insurer says no, and what fixes it
Most first-fill delays are one of these. Knowing which one tells you who to call.
- Prior authorization pending or deniedThe FEP policy below asks for more than the label does. It wants a positive AChR or MuSK antibody test, an MGFA class of II to IV and a documented baseline MG-ADL or QMG score. The neurologist's records usually answer what the plan is asking for.FEP Blue policy
- The plan wants another medicine tried firstThe FEP policy asks that one listed medicine did not work well enough, was not tolerated or cannot be used. Its list is an acetylcholinesterase inhibitor, azathioprine, cyclosporine, mycophenolate mofetil, tacrolimus, methotrexate or cyclophosphamide. Your neurologist documents which one applies.FEP Blue policy
- Screening results are missingHepatitis B, tuberculosis and antibody level results are required before the first dose. Amgen says your liaison can help with steps such as completing required labs and checking what the prior authorization still needs.Amgen insurance page
- The plan says no after reviewAmgen describes 2 next steps. Your doctor can ask for a medical exception with extra paperwork, or you and the office can appeal. The Amgen By Your Side team can explain both.Amgen insurance page
- A copay you cannot payCommercial insurance: the Amgen Commercial Co-Pay Program, as little as $0 for Uplizna and infusion costs. Medicare, Medicaid, VA, TRICARE and other government coverage are excluded. Our help paying page lists charity funds that may cover what remains.Amgen financial support
- You live in Massachusetts or Rhode IslandAmgen's co-pay terms say residents of these 2 states are not eligible for administration support. That is the part of the program that covers the cost of giving the infusion.Amgen financial support
- Medicare, Medicaid or no insuranceThe co-pay program does not apply. Amgen lists independent funds such as The Assistance Fund, Good Days, the PAN Foundation and NORD. Each sets its own rules, and Amgen does not run them.Amgen financial support
- The renewal after a yearThe FEP policy renews for 12 months at a time, with up to 6 vials. For myasthenia gravis, it asks for a drop of at least 2 points in the MG-ADL or QMG score from baseline.FEP Blue policy
Blue Cross Blue Shield Federal Employee Program prior authorization policy, April 1, 2026
- Age 18 or older
- Generalized myasthenia gravis with autoantibodies against AChR or MuSK
- Myasthenia Gravis Foundation of America (MGFA) clinical classification class II to IV
- A documented baseline score: MG-ADL of 11 or higher, MG-ADL of 6 to 10 with at least 50% from non-ocular items, or QMG of 11 or higher
- Inadequate response, intolerance or contraindication to one of these: an acetylcholinesterase inhibitor, azathioprine, cyclosporine, mycophenolate mofetil, tacrolimus, methotrexate or cyclophosphamide
- No active hepatitis B infection
- No active or untreated latent tuberculosis
- Not given at the same time as live vaccines
- Females who could become pregnant are advised to use effective birth control during treatment and for 6 months after the last dose
Approval length. Twelve months at first, up to 9 vials. Renewals are 12 months at a time, up to 6 vials, when the MG-ADL or QMG total score has dropped at least 2 points from baseline.
This policy was approved on March 6, 2026 and cites the December 2025 label. It predates the September 2026 label, which changed only how pharmacists draw the medicine from the vial. The MGFA class, baseline score and earlier-medicine criteria are the plan's own and are not conditions in the label. It is here as an example of what a plan asks for, not as a rule. FEP Blue policy
Who to call, and what they can do
The drugmaker's program handles most of the first-fill problems above. Charity funds and foundation help are on the help paying page.
- A dedicated Patient Access Liaison who explains insurance, costs and appointments, and helps find an infusion center
- A benefits investigation after you sign a HIPAA release: what your plan covers, your likely costs and whether a prior authorization is needed Amgen insurance page
- The Amgen Commercial Co-Pay Program, as little as $0 out of pocket for Uplizna and infusion costs for eligible commercial insurance Amgen financial support
- Eligibility criteria and program maximums apply to the co-pay program; Amgen's pages give no dollar figure for the maximum Uplizna site
- Co-pay help is not open to Medicare, Medicaid, Medigap, VA, CHAMPUS, DOD, TRICARE or other government coverage, under the program's terms Amgen financial support
- Residents of Massachusetts or Rhode Island are not eligible for the infusion administration part of the co-pay help Amgen financial support
- A list of independent charity funds: The Assistance Fund, Good Days, the PAN Foundation and NORD Amgen financial support
Details as the drugmaker publishes them. Amgen By Your Side
Five questions for the pharmacist or the support line
- Are my hepatitis B, tuberculosis and antibody level results already on file with the infusion center?
- Which vaccines do I still need, and is there time to get them 4 weeks before my first infusion?
- Will I get my steroid, antihistamine and fever reducer at the infusion center, or do I take some at home first?
- How long should I plan to stay, counting the premedicines, the 90-minute infusion and the hour of watching?
- Has my co-pay program been applied to both the medicine and the infusion fee?
- Who books my 6-month infusion, and when does my insurance approval need renewing?
Questions people ask in the first weeks
How long does it take to start Uplizna after it is prescribed?
There is no fixed number of days. Three screening tests, any needed vaccines 4 weeks ahead, the benefits check, prior authorization and booking an infusion site each take their own time. Amgen says your Patient Access Liaison can update you on the insurance review as it moves.
How often is Uplizna given for myasthenia gravis?
Twice a year after 2 starting doses. The label gives 300mg, then another 300mg 2 weeks later, then one 300mg infusion every 6 months counted from the first infusion.
Which antibody types does Uplizna cover in myasthenia gravis?
The label covers adults with generalized myasthenia gravis who test positive for AChR or MuSK antibodies. The trial in the label enrolled 190 people with AChR antibodies and 48 with MuSK antibodies, and nobody without one of them.
What tests do I need before my first Uplizna infusion?
The label requires hepatitis B screening, a check for active and latent tuberculosis and a blood test of immunoglobulin levels. Uplizna is not given with active hepatitis B or active or untreated latent tuberculosis.
Do I need vaccines before starting Uplizna?
The label asks for all vaccines by the usual guidelines at least 4 weeks before the first infusion. Live vaccines are not recommended during treatment or until your B cells recover after stopping.
What did the myasthenia gravis trial in the label show?
The trial randomized 238 adults to Uplizna or placebo. At week 26, the MG-ADL score, a 0 to 24 rating of daily activities, improved by 4.2 points on Uplizna and 2.2 on placebo. The QMG score, a 0 to 39 rating of muscle weakness, improved by 4.8 points against 2.3.
Can I keep taking my other myasthenia gravis medicines?
That is your neurologist's decision. Everyone in the trial entered on a stable dose of a steroid, another immune-suppressing medicine or both, and about 79% took an acetylcholinesterase inhibitor. The label says combining Uplizna with immune-suppressing drugs, including steroids, may raise the risk of infection.
Is Uplizna used for other conditions?
Yes, the label also covers AQP4 antibody positive NMOSD and IgG4-related disease in adults, with the same dose schedule. This page covers only generalized myasthenia gravis.
Free email alert
Hear when the Uplizna label changes
One email the day the FDA revises the Uplizna label, with what changed in plain words. No trial alerts, no newsletter.
Label changes for Uplizna only, usually a few a year and some years none. Stop anytime. We never share your email. Privacy policy
Want the whole condition instead? Follow Generalized myasthenia gravis for new trials, FDA decisions and label changes for every treatment.
Sources
- DailyMed - UPLIZNA- inebilizumab injection (prescribing information revised September 2026, SPL version 11, and Medication Guide), Horizon Therapeutics USA (Amgen), via DailyMed, September 21, 2026.
- Cost, Savings, and Support | UPLIZNA® (inebilizumab-cdon), Amgen, November 13, 2026.
- What to Expect | UPLIZNA® (inebilizumab-cdon), Amgen, November 13, 2026.
- UPLIZNA® Insurance Coverage | Amgen By Your Side, Amgen, November 13, 2026.
- UPLIZNA® Financial Support Programs | Amgen By Your Side, Amgen, November 13, 2026.
- Frequently Asked Questions (FAQs) for UPLIZNA® | Amgen By Your Side, Amgen, November 13, 2026.
- Official Consumer Website | UPLIZNA® (inebilizumab-cdon), Amgen, November 13, 2026.
- Pharmacy Policy 5.99.018, Uplizna, Blue Cross Blue Shield Federal Employee Program, April 1, 2026.
- BLA 761142/S-004 supplement approval letter, generalized myasthenia gravis, FDA, December 11, 2025.
- BLA 761142/S-003 supplement approval letter, immunoglobulin G4-related disease, FDA, April 3, 2025.
- BLA 761142 approval letter, Uplizna (inebilizumab-cdon) for NMOSD, FDA, June 11, 2020.
This page explains what the FDA label, the drugmaker's support program and an insurer policy say. It is not medical advice and does not tell anyone to start, stop or change a medicine. Dosing, test timing and restarts after a gap are decisions for the prescribing neurologist. Found an error? Use the report link in the footer and it will be checked against the source.